MX2022007464A - Composiciones biofarmaceuticas y metodos relacionados. - Google Patents
Composiciones biofarmaceuticas y metodos relacionados.Info
- Publication number
- MX2022007464A MX2022007464A MX2022007464A MX2022007464A MX2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A
- Authority
- MX
- Mexico
- Prior art keywords
- related methods
- biopharmaceutical compositions
- compositions
- biopharmaceutical
- antagonism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949696P | 2019-12-18 | 2019-12-18 | |
| US201962950595P | 2019-12-19 | 2019-12-19 | |
| PCT/US2020/064241 WO2021126657A1 (en) | 2019-12-18 | 2020-12-10 | Biopharmaceutical compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007464A true MX2022007464A (es) | 2022-06-27 |
Family
ID=74125707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007464A MX2022007464A (es) | 2019-12-18 | 2020-12-10 | Composiciones biofarmaceuticas y metodos relacionados. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230059341A1 (https=) |
| EP (1) | EP4077388A1 (https=) |
| JP (2) | JP2023507981A (https=) |
| KR (1) | KR20220129548A (https=) |
| CN (1) | CN115298218A (https=) |
| AU (2) | AU2020407007A1 (https=) |
| BR (1) | BR112022014694A2 (https=) |
| CA (1) | CA3164600A1 (https=) |
| IL (1) | IL293753A (https=) |
| MX (1) | MX2022007464A (https=) |
| WO (1) | WO2021126657A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4076385T1 (sl) * | 2019-12-20 | 2026-04-30 | Formycon Ag | Formulacije protiteles anti-pd1 |
| WO2024118587A1 (en) * | 2022-11-30 | 2024-06-06 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1-antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015017307A2 (pt) * | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| KR20180037275A (ko) * | 2015-08-24 | 2018-04-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 생물제약 조성물 |
| CN106999591B (zh) * | 2015-09-28 | 2021-02-23 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体制剂及其在医药上的应用 |
| LT3386541T (lt) * | 2015-12-07 | 2020-10-26 | Merck Patent Gmbh | Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą |
| JP2019533458A (ja) * | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
-
2020
- 2020-12-10 WO PCT/US2020/064241 patent/WO2021126657A1/en not_active Ceased
- 2020-12-10 CN CN202080094093.2A patent/CN115298218A/zh active Pending
- 2020-12-10 BR BR112022014694A patent/BR112022014694A2/pt not_active Application Discontinuation
- 2020-12-10 KR KR1020227024058A patent/KR20220129548A/ko active Pending
- 2020-12-10 EP EP20835967.9A patent/EP4077388A1/en active Pending
- 2020-12-10 MX MX2022007464A patent/MX2022007464A/es unknown
- 2020-12-10 AU AU2020407007A patent/AU2020407007A1/en not_active Abandoned
- 2020-12-10 CA CA3164600A patent/CA3164600A1/en active Pending
- 2020-12-10 IL IL293753A patent/IL293753A/en unknown
- 2020-12-10 US US17/785,506 patent/US20230059341A1/en active Pending
- 2020-12-10 JP JP2022537240A patent/JP2023507981A/ja active Pending
-
2025
- 2025-05-23 AU AU2025203823A patent/AU2025203823A1/en active Pending
- 2025-11-04 JP JP2025185522A patent/JP2026027328A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2025203823A1 (en) | 2025-06-19 |
| JP2023507981A (ja) | 2023-02-28 |
| IL293753A (en) | 2022-08-01 |
| CN115298218A (zh) | 2022-11-04 |
| EP4077388A1 (en) | 2022-10-26 |
| AU2020407007A1 (en) | 2022-06-23 |
| CA3164600A1 (en) | 2021-06-24 |
| WO2021126657A1 (en) | 2021-06-24 |
| JP2026027328A (ja) | 2026-02-18 |
| US20230059341A1 (en) | 2023-02-23 |
| BR112022014694A2 (pt) | 2022-09-06 |
| KR20220129548A (ko) | 2022-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004003A2 (es) | Composiciones y anticuerpos anti-lag-3 | |
| CO2020014345A2 (es) | Anticuerpos específicos para gucy2c y sus usos | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| PE20211412A1 (es) | Anticuerpos anti-gdf15, composiciones y metodos de uso | |
| UY37957A (es) | Moduladores de la vía de estrés integrada | |
| PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
| CO2019012080A2 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| UY37956A (es) | Moduladores de la vía de estrés integrada | |
| BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
| AU2018263868A1 (en) | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| UY37958A (es) | Moduladores de la vía de estrés integrada | |
| CO2017010618A2 (es) | Anticuerpos contra icos | |
| BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
| UY37230A (es) | Moduladores de la vía de estrés integrada | |
| UY37231A (es) | Moduladores de la vía de estrés integrada | |
| BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
| CR20180574A (es) | Moduladores de la vía de estrés integrada | |
| MX2017000985A (es) | Anticuerpos anti-pd-1. | |
| JOP20200177A1 (ar) | طرق علاج السرطان باستخدام الأجسام المضادة anti-pd-1 المناهضة | |
| UY37229A (es) | Moduladores de la vía de estrés integrada | |
| CR20170011A (es) | Compuestos de heteroarilo para la inhibición de cinasa | |
| BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
| CO2018005393A2 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos |